Brief: IRLAB Posts Positive Topline Results From IRL757 Phase I Study

IRLAB Therapeutics AB

31/01/2025 06:00

Jan 31 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB REPORTS POSITIVE TOPLINE RESULTS FROM PHASE I STUDY
WITH
IRL757 IN HEALTHY OLDER ADULTS
    * RESULTS SHOW THAT IRL757 IS WELL ABSORBED AND PROVIDES
GOOD
EXPOSURE IN BODY
    * ALL PARTICIPANTS COMPLETED STUDY, AND NO SERIOUS ADVERSE
EVENTS
WERE RECORDED
    * COLLECTIVELY, SAFETY, TOLERABILITY AND PHARMACOKINETIC
PROFILE
SUPPORTS FURTHER DEVELOPMENT OF IRL757
    * DRUG CANDIDATE IRL757 HAS SHOWN POSITIVE EFFECTS IN
SEVERAL
PRECLINICAL MODELS OF COGNITIVE FUNCTION, INCLUDING IMPROVED
MOTIVATION

Source text:  ID:nMFN818fxg 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))